Global Surrogacy Market Expected to Reach US$ 11.94 Billion by 2034 │ The Insight Partners

The Insight Partners estimates the global surrogacy market will grow from $5.38B in 2025 to $11.94B by 2034 (9.3% CAGR, 2026-2034), supported by rising infertility and delayed parenthood. Demand is strongest in gestational surrogacy, with North America leading, while Asia Pacific is expected to offer the fastest long-term growth. The report highlights incremental positives from expanding employer fertility benefits (e.g., Cigna/Progyny collaboration) and technology advances (e.g., IVF improvements, cryopreservation, genetic screening), tempered by legal variability, cross-border restrictions, high costs, and ethical governance needs.

Analysis

The economic value here accrues less to clinics and more to the distribution layer that can turn a niche, high-friction service into a reimbursable employee benefit. That favors PGNY: if employers keep adding family-building coverage, the company captures both higher utilization and deeper wallet share without needing to own the clinical assets. By contrast, CI can participate only if it can price the benefit cleanly; otherwise fertility/surrogacy is a claims-cost add-on that helps retention but dilutes underwriting margin.

Second-order, the real winners are integrated navigation platforms and large clinic networks with employer contracts, while fragmented agencies and cross-border specialists should see less durable pricing power. Publicly traded clinic operators would likely gain volume faster than profits because the bottleneck is legal coordination, screening, and payer paperwork rather than raw procedure capacity. In a weaker labor market, employers may still advertise these benefits, but adoption can slow as HR teams push for tighter prior-auth and narrower networks.

The catalyst path is months, not days: watch for employer benefit renewals, guidance on covered lives, and any evidence that surrogacy is becoming a standard add-on rather than a premium feature. The contrarian risk is that the market extrapolates TAM growth from a small, highly regulated base; much of the forecast may be inflation and benefit mix, not pure unit growth. If PGNY fails to show accelerating client wins or higher enrollment conversion over the next 1-2 quarters, the thesis fades quickly.

Key Decisions for Investors

• Long PGNY on pullbacks over the next 1-3 months; best risk/reward if management can show higher employer penetration and stable gross margin from navigation/services mix.
• Small relative-value pair: long PGNY / short CI into earnings or benefits commentary, sized modestly because CI is only an indirect hedge; thesis works if fertility benefits grow faster than CI can reprice them.
• No chase in NIVF or other small fertility names until there is evidence of profitable employer-channel traction; the sector’s legal and reimbursement complexity makes headline TAM a poor standalone signal.
• Set a watch item on PGNY covered-lives growth and client concentration; thesis is falsified if new wins slow or if utilization comes with lower-than-expected take-rate.